Class Action: Janssen Adds GSK’s NS5a Inhibitor To Its Hepatitis C Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
With protease inhibitor simeprevir filed for approval in the U.S., Europe and Japan, and a non-nucleoside polymerase inhibitor in Phase II, adding GSK2336805, also in Phase II, gives the J&J unit three different classes of oral antiviral candidates for HCV.